• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: cancer immunotherapy market to hit $9B globally by 2022

Report: cancer immunotherapy market to hit $9B globally by 2022

July 9, 2014
CenterWatch Staff

Decision Resources Group reports the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the U.S., France, Germany, Italy, Spain, U.K. and Japan.

This growth will be driven by the expected market entry of nine novel immunotherapies—including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations.

Interviewed experts are considerably optimistic about the potential of anti-PD-1/PD-L1 agents based on promising data released to date in multiple oncology indications. The added prospect of using PD-L1 expression as a potential predictive biomarker for personalizing treatment intrigues interviewed experts; however, they remain cautious on this point, noting that considerable heterogeneity exists in PD-L1 expression and that good objective responses also have been reported in patients deemed to have no or low levels of PD-L1 expression.

Owing to impressive early-phase data presented at the 2014 annual meeting of the American Society for Clinical Oncology (ASCO), interviewed experts express enthusiasm for combination approaches involving immunotherapies—including dual blockade of the immune checkpoint pathway, combinations of immune checkpoint inhibitors with therapeutic cancer vaccines and combinations of immune checkpoint inhibitors with chemotherapy.

The therapeutic vaccines segment will witness 13.6% annual sales growth over the 2012 to 2022 forecast period, although, with combined major-market sales reaching $1.2 billion in 2022, these agents will fall short of replicating the commercial success of immune checkpoint inhibitors.

Khurram Nawaz, Decision Resources Group senior business insights analyst, said, “We anticipate that nivolumab will be the sales-leading agent among immunotherapies. However, it will face direct and intense competition from other anti-PD-1/PD-L1 agents—notably from pembrolizumab in malignant melanoma and non-small-cell lung cancer—and, to a lesser extent, from MPDL-3280A in non-small-cell lung cancer.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing